Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • giredestrant (GDC-9545) • inavolisib (GDC-0077)

Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial. (PubMed, Eur Urol Oncol)

Adding AAP to salvage radiation therapy and goserelin resulted in high bRFS and alt-bRFS. AEs remained manageable, although a close liver surveillance is advised. CTC count appears as a promising biomarker for prognosis and predicting response to treatment.

3 days ago

P2 data • Journal

AR (Androgen receptor)

abiraterone acetate • goserelin acetate

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov)

P2, N=19, Active, not recruiting, University of Colorado, Denver | Trial completion date: Apr 2024 --> Apr 2025

9 days ago

Trial completion date

Xtandi (enzalutamide capsule) • triptorelin • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension

19d

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (clinicaltrials.gov)

P2, N=40, Recruiting, The First Affiliated Hospital of Xiamen University

19 days ago

New P2 trial • Metastases

cisplatin • docetaxel • Tevimbra (tislelizumab) • Partruvix (pamiparib) • goserelin acetate • Airui'en (rezvilutamide)

19d

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer (clinicaltrials.gov)

P2, N=60, Recruiting, The First Affiliated Hospital of Xiamen University

19 days ago

New P2 trial

goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)

21d

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov)

P2, N=60, Active, not recruiting, Xiao X. Wei, MD | Recruiting --> Active, not recruiting

21 days ago

Enrollment closed • Combination therapy • Metastases

PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • GEN1 (GEN1 Holliday junction 5' flap endonuclease)

PD-L1 expression • MSI-H/dMMR

OncoPanel™ Assay

Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension

21d

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov)

P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024

21 days ago

Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world • Metastases

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • leuprolide acetate for depot suspension

21d

ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov)

P3, N=3100, Suspended, Novartis Pharmaceuticals | Recruiting --> Suspended

21 days ago

Trial suspension

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • HER-2 negative • PGR positive

Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension

21d

DUCT: Phase II Dutasteride in Combination With CAB vs CAB in SDC (clinicaltrials.gov)

P2, N=26, Recruiting, Radboud University Medical Center | N=98 --> 26

21 days ago

Enrollment change • Combination therapy • Metastases

AR (Androgen receptor)

AR positive

bicalutamide • goserelin acetate

22d

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (clinicaltrials.gov)

P2, N=120, Not yet recruiting, Mayo Clinic

22 days ago

New P2 trial • Metastases

Xtandi (enzalutamide capsule) • abiraterone acetate • Nubeqa (darolutamide) • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension

28d

PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov)

P2, N=257, Completed, Palleos Healthcare GmbH | Active, not recruiting --> Completed

28 days ago

Trial completion • HEOR • Combination therapy

HER-2 (Human epidermal growth factor receptor 2)

Herceptin (trastuzumab) • paclitaxel • tamoxifen • Perjeta (pertuzumab) • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension

29d

BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov)

P2, N=550, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

29 days ago

Enrollment closed

ER (Estrogen receptor)

Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov)

P=N/A, N=42, Active, not recruiting, Medical College of Wisconsin | N=60 --> 42

1 month ago

Enrollment change

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • bicalutamide • Erleada (apalutamide) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (clinicaltrials.gov)

P2, N=79, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed • Metastases

Xtandi (enzalutamide capsule) • goserelin acetate

EORTC-1532: ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer (clinicaltrials.gov)

P2, N=61, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: May 2024 --> Dec 2036

1 month ago

Trial completion date

Nubeqa (darolutamide) • triptorelin • goserelin acetate • Firmagon (degarelix)

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)

P2, N=74, Not yet recruiting, University of Chicago

1 month ago

New P2 trial

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)

2ms

YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov)

P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: May 2024 --> Sep 2025

2 months ago

Trial completion date • Combination therapy • Metastases

AR (Androgen receptor)

AR positive • AR expression

Erleada (apalutamide) • goserelin acetate

2ms

PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)

P3, N=412, Recruiting, Janssen Pharmaceutica N.V., Belgium | Trial completion date: Jan 2030 --> Aug 2029 | Trial primary completion date: Jan 2030 --> Aug 2029

2 months ago

Trial completion date • Trial primary completion date

Erleada (apalutamide) • triptorelin • goserelin acetate

2ms

ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov)

P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2024

2 months ago

Trial completion date • Trial primary completion date

ER (Estrogen receptor)

ER positive

Ibrance (palbociclib) • tamoxifen • Bavencio (avelumab) • Eligard (leuprolide acetate) • goserelin acetate

2ms

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan (clinicaltrials.gov)

P=N/A, N=979, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025

2 months ago

Trial completion date • Trial primary completion date • Metastases

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • bicalutamide • Erleada (apalutamide) • goserelin acetate

2ms

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov)

P3, N=315, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024

2 months ago

Trial completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)

carboplatin • docetaxel • Trazimera (trastuzumab-qyyp) • goserelin acetate • TQB2440 (pertuzumab biosimilar) • BCD-178 (pertuzumab biosimilar)

2ms

Ribociclib plus Endocrine Therapy in Early Breast Cancer. (PubMed, N Engl J Med)

Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).

2 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 negative • EGFR positive • PTEN mutation + HR positive

Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate

2ms

PATHWAY: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (clinicaltrials.gov)

P3, N=180, Active, not recruiting, National Cancer Center, Japan | Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025

2 months ago

Trial completion date • Trial primary completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2)

HER-2 negative

Ibrance (palbociclib) • tamoxifen • goserelin acetate

2ms

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer (clinicaltrials.gov)

P=N/A, N=25, Recruiting, Washington University School of Medicine | Trial completion date: Jan 2030 --> Jan 2031 | Trial primary completion date: Apr 2025 --> Apr 2026

2 months ago

Trial completion date • Trial primary completion date

goserelin acetate

2ms

FINEST: A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC (clinicaltrials.gov)

P1/2, N=20, Recruiting, Fudan University | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024

2 months ago

Trial completion date • Trial primary completion date

carboplatin • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • goserelin acetate

3ms

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (clinicaltrials.gov)

P1/2, N=93, Active, not recruiting, Praful Ravi, MB BCHir, MRCP | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

Verzenio (abemaciclib) • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • goserelin acetate • Firmagon (degarelix)

3ms

THUNDER: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (clinicaltrials.gov)

P2/3; N=493; Recruiting; Sponsor:Cancer Research Antwerp

3 months ago

New P2/3 trial

Decipher Prostate Cancer Test

docetaxel • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Firmagon (degarelix)

3ms

ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov)

P3, N=3100, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • HER-2 negative • PGR positive

Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension

3ms

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (clinicaltrials.gov)

P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P1b --> P1

3 months ago

Phase classification

abiraterone acetate • prednisone • triptorelin • goserelin acetate

3ms

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)

P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

3 months ago

Trial completion date • Metastases

Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Viadur (leuprorelin implant)

3ms

ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov)

P3, N=3100, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jul 2028 --> Sep 2029

3 months ago

Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • HER-2 negative • PGR positive

Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension

3ms

LEANORA: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (clinicaltrials.gov)

P4, N=21, Terminated, Georgetown University | Trial completion date: Jul 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Sufficient accrual into the African American/Black patient cohort and insufficient accrual into the NHW patient cohort.

3 months ago

Trial completion date • Trial termination

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

ER positive • HER-2 negative

Kisqali (ribociclib) • fulvestrant • goserelin acetate

3ms

SAVE: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (clinicaltrials.gov)

P2, N=202, Recruiting, Cancer Research Antwerp | Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025

3 months ago

Trial completion date • Trial primary completion date • Combination therapy

Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension

3ms

BTCRC-HN17-111: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma (clinicaltrials.gov)

P2, N=20, Recruiting, Manish Patel | Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Dec 2023 --> Mar 2024

3 months ago

Trial completion date • Trial primary completion date • Metastases

AR (Androgen receptor)

AR positive

Keytruda (pembrolizumab) • goserelin acetate

3ms

A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov)

P=N/A, N=960, Completed, Bayer | Active, not recruiting --> Completed

3 months ago

Trial completion

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • Eligard (leuprolide acetate) • triptorelin • goserelin acetate • cyproterone acetate

3ms

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (clinicaltrials.gov)

P2; Not yet recruiting --> Recruiting

3 months ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2)

HER-2 negative

Prosigna™ Breast Cancer Prognostic Gene Signature Assay

everolimus • fulvestrant • exemestane • AiRuiKang (dalpiciclib) • goserelin acetate

3ms

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov)

P1, N=20, Completed, Medical University of South Carolina | Active, not recruiting --> Completed

3 months ago

Trial completion

docetaxel • bicalutamide • goserelin acetate • leuprolide acetate for depot suspension

4ms

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer (clinicaltrials.gov)

P3, N=68, Recruiting, Eurofarma Laboratorios S.A. | Trial completion date: Jun 2025 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Sep 2024

4 months ago

Trial completion date • Trial primary completion date

ER (Estrogen receptor)

ER positive

goserelin acetate

4ms

ESCALATE: Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (clinicaltrials.gov)

P2, N=124, Not yet recruiting, National Taiwan University Hospital

4 months ago

New P2 trial

docetaxel • cyclophosphamide • triptorelin • goserelin acetate • leuprolide acetate for depot suspension

4ms

Zoladex® 10.8 BC RWS (clinicaltrials.gov)

P=N/A, N=1176, Completed, AstraZeneca | Recruiting --> Completed

4 months ago

Trial completion • Real-world evidence • Real-world

HR positive

goserelin acetate

4ms

NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (clinicaltrials.gov)

P2, N=32, Recruiting, Rana McKay, MD | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025

4 months ago

Trial completion date • Trial primary completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension

4ms

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov)

P2, N=70, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027

4 months ago

Trial completion date • Trial primary completion date

Talzenna (talazoparib) • abiraterone acetate • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Firmagon (degarelix) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)